NCT00372697View on ClinicalTrials.gov

Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly

PHASE3CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Acromegaly
Interventions
DRUG

Octreotide acetate 30 mg suspension

Each vial of study medication contained octreotide acetate 30 mg in a microencapsulated biodegradable polymer, poly (DL-lactide-co-glycolide) (D-(+)glucose), with 17% w/w mannitol in an approximate octreotide:polymer ratio of 1:20. The vehicle contained 0.5% sodium carboxymethylcellulose.

Trial Locations (1)

Unknown

Novartis Investigative Site, Brescia

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY